Business Description
TC BioPharm (Holdings) PLC
ISIN : US87807D4007
Share Class Description:
TCBP: ADRDescription
TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.61 | |||||
Equity-to-Asset | 0.29 | |||||
Debt-to-Equity | 0.83 | |||||
Debt-to-EBITDA | -0.32 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EPS without NRI Growth Rate | 40.4 |
Momentum Rank
3/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 21.93 | |||||
9-Day RSI | 24.73 | |||||
14-Day RSI | 27.51 | |||||
3-1 Month Momentum % | -17.17 | |||||
6-1 Month Momentum % | -91.67 | |||||
12-1 Month Momentum % | -96.32 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.12 | |||||
Quick Ratio | 1.12 | |||||
Cash Ratio | 0.28 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Shareholder Yield % | 1.35 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -274.3 | |||||
ROA % | -68.16 | |||||
ROIC % | -136.89 | |||||
3-Year ROIIC % | 198.13 | |||||
ROC (Joel Greenblatt) % | -219.43 | |||||
ROCE % | -161.28 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 1.73 | |||||
Price-to-Tangible-Book | 2.47 | |||||
EV-to-EBIT | -10.55 | |||||
EV-to-EBITDA | -11.05 | |||||
EV-to-Forward-Revenue | 0.01 | |||||
EV-to-FCF | -11.18 | |||||
Earnings Yield (Greenblatt) % | -9.48 | |||||
FCF Yield % | -9.04 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:TCBP
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
TC BioPharm (Holdings) PLC Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -529.043 | ||
Beta | -0.15 | ||
3-Year Sharpe Ratio | - | ||
3-Year Sortino Ratio | - | ||
Volatility % | 104.81 | ||
14-Day RSI | 27.51 | ||
14-Day ATR ($) | 0.856312 | ||
20-Day SMA ($) | 3.77335 | ||
12-1 Month Momentum % | -96.32 | ||
52-Week Range ($) | 1.91 - 523.2 | ||
Shares Outstanding (Mil) | 0.51 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
TC BioPharm (Holdings) PLC Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
TC BioPharm (Holdings) PLC Stock Events
Event | Date | Price ($) | ||
---|---|---|---|---|
No Event Data |
TC BioPharm (Holdings) PLC Frequently Asked Questions
What is TC BioPharm (Holdings) PLC(TCBP)'s stock price today?
The current price of TCBP is $2.00. The 52 week high of TCBP is $523.20 and 52 week low is $1.91.
When is next earnings date of TC BioPharm (Holdings) PLC(TCBP)?
The next earnings date of TC BioPharm (Holdings) PLC(TCBP) is .
Does TC BioPharm (Holdings) PLC(TCBP) pay dividends? If so, how much?
TC BioPharm (Holdings) PLC(TCBP) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |